Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Indivior PLC Ordinary Shares (INDV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/01/2025: INDV (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19
1 Year Target Price $19
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 35.11% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.84B USD | Price to earnings Ratio - | 1Y Target Price 19 |
Price to earnings Ratio - | 1Y Target Price 19 | ||
Volume (30-day avg) 7 | Beta 0.25 | 52 Weeks Range 7.33 - 15.50 | Updated Date 07/1/2025 |
52 Weeks Range 7.33 - 15.50 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -5.3% | Operating Margin (TTM) 25.56% |
Management Effectiveness
Return on Assets (TTM) 12.6% | Return on Equity (TTM) 12.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1852456663 | Price to Sales(TTM) 1.57 |
Enterprise Value 1852456663 | Price to Sales(TTM) 1.57 | ||
Enterprise Value to Revenue 1.58 | Enterprise Value to EBITDA 25.38 | Shares Outstanding 124770000 | Shares Floating 89522140 |
Shares Outstanding 124770000 | Shares Floating 89522140 | ||
Percent Insiders 4.02 | Percent Institutions 89.09 |
Analyst Ratings
Rating 2 | Target Price 19 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Indivior PLC Ordinary Shares
Company Overview
History and Background
Indivior PLC (formerly Reckitt Benckiser Pharmaceuticals) is a global pharmaceutical company headquartered in the UK. It focuses on developing, manufacturing, and commercializing medicines to treat opioid use disorder (OUD) and other substance use disorders. The company was founded in 2014 following a demerger from Reckitt Benckiser Group.
Core Business Areas
- Opioid Dependence Treatment: Develops and markets medications, including Suboxone and Sublocade, to treat opioid use disorder (OUD).
- Alcohol Dependence Treatment: Focuses on developing medications for treating alcohol use disorder (AUD).
- Pipeline Products: Research and development of new treatments for substance use disorders, including potential medications and therapies.
Leadership and Structure
Indivior is led by a Chief Executive Officer (CEO) and a senior management team. The company has a Board of Directors responsible for governance and strategic oversight. The organizational structure is based on functional areas such as research and development, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- Suboxone (buprenorphine/naloxone): A sublingual film used to treat opioid dependence. Indivior was one of the earliest to market, but its patent exclusivity has expired, facing intense generic competition. Market share has decreased over time, but it remains a significant contributor to revenue. Competitors include Mylan (Viatris), Teva Pharmaceutical Industries, and generic manufacturers. Exact market share is difficult to pin down currently due to multiple generics, but it is estimated to be under 20% of the Buprenorphine/Naloxone market.
- Sublocade (buprenorphine extended-release): A once-monthly injectable formulation of buprenorphine for the treatment of moderate to severe opioid use disorder. Sublocade is the leading injectable buprenorphine product. Competitors include Camurus' Brixadi. Sublocade has a significant market share in the injectable buprenorphine segment, with estimates exceeding 80% within that niche. Sublocade revenue represents the bulk of Indivior's revenue.
Market Dynamics
Industry Overview
The market for opioid dependence treatment is driven by the opioid crisis and growing awareness of substance use disorders. The industry is characterized by a mix of branded and generic medications. Key players include pharmaceutical companies, specialty pharmacies, and healthcare providers.
Positioning
Indivior has a strong position in the opioid dependence treatment market, particularly with its Sublocade product. It competes with generic manufacturers in the sublingual buprenorphine market, but its injectable product offers a competitive advantage. Indivior continues to invest in R&D to expand its product portfolio and maintain its market position.
Total Addressable Market (TAM)
The opioid use disorder (OUD) treatment market is estimated at several billion dollars globally and is expected to grow due to the ongoing opioid crisis. Indivior is positioned to capture a significant portion of this TAM, particularly with its Sublocade injectable product, although competition is increasing.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in opioid dependence treatment.
- Leading position in the injectable buprenorphine market (Sublocade).
- Established distribution network.
- Experienced management team.
- Focus on R&D for innovative treatments.
Weaknesses
- Dependence on a limited number of key products.
- Patent expiration of key products (e.g., Suboxone).
- Exposure to generic competition.
- Potential litigation risks related to past marketing practices.
- High R&D costs.
Opportunities
- Expansion into new geographic markets.
- Development of new treatments for substance use disorders.
- Partnerships with healthcare providers and payers.
- Increased government funding for addiction treatment.
- Leveraging digital health technologies to improve treatment adherence.
Threats
- Increased competition from generic manufacturers.
- Changes in regulatory requirements.
- Price pressures from payers.
- Potential for new, more effective treatments to emerge.
- Negative publicity or litigation related to opioid addiction.
Competitors and Market Share
Key Competitors
- OTCQX:CMURF
- TEVA
- VTRS
Competitive Landscape
Indivior's advantage lies in its Sublocade injectable formulation. However, it faces increasing competition from generics and other branded products. Its success depends on its ability to maintain market share and innovate new treatments.
Major Acquisitions
Opiant Pharmaceuticals
- Year: 2023
- Acquisition Price (USD millions): 145
- Strategic Rationale: Acquisition provides access to novel overdose treatment assets and expands Indivior's portfolio beyond OUD.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been mixed, with declines in legacy product sales (Suboxone) offset by growth in Sublocade sales.
Future Projections: Future growth projections are dependent on continued Sublocade adoption, success of pipeline products, and market dynamics. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding Sublocade access, developing new formulations, and exploring new therapeutic areas.
Summary
Indivior demonstrates a mixed profile, possessing a strong hold within the injectable opioid dependence treatment market via Sublocade, yet facing revenue pressures from generic competition impacting their older products. Their market dominance in injectables and recent acquisitions signal a strategic shift toward diversification. Despite their strengths, Indivior must remain vigilant regarding competition, regulatory shifts, and legal hurdles. Maintaining growth requires continued innovation and adapting to changing market conditions, which may include further acquisitions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be construed as financial advice. Market share data is estimated and may not be precise. Investment decisions should be based on thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Indivior PLC Ordinary Shares
Exchange NASDAQ | Headquaters North Chesterfield, VA, United States | ||
IPO Launch date 2014-12-29 | CEO & Director Mr. Joseph J. Ciaffoni | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1030 | Website https://www.indivior.com |
Full time employees 1030 | Website https://www.indivior.com | ||
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.